Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Borussia Dortmund have agreed a new deal with Under-19 head coach Mike Tullberg, the club have announced. In the process of ...

A tricky buy-out clause coupled with the start date of the FIFA Club World Cup is complicating BVB’s intentions with Carney ...

Borussia Dortmund have agreed a new deal with Under-19 head coach Mike Tullberg, the club have announced. In the process of ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...

DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.